Atlas Venture — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Dyne Therapeuticsdyne-tx.comin𝕏NASDAQ: DYNAug 2020
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Lawrence Klein, Ph.D.(Director)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)David Lubner(Director)Edward Hurwitz(Director)Dirk Kersten(Director)
Aerovate Therapeutics, Inc.Aug 2020SEC filingmedium confidence
Boston, US
Board seatDavid Grayzel· per SEC Form D · $75.8M raise · filed Aug 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.